Teriparatide is a medication primarily used for the treatment of osteoporosis, a condition characterized by low bone density and increased risk of fractures. It is a synthetic form of parathyroid hormone (PTH), which is a hormone naturally produced by the parathyroid glands in the body.

Teriparatide acts by mimicking the action of PTH in the body. It works to stimulate bone formation, increase bone mineral density, and enhance bone strength. Unlike other osteoporosis medications that primarily focus on slowing down bone loss, teriparatide is unique in its ability to promote bone formation and improve bone quality.


The medication is administered through daily subcutaneous injections, typically in the thigh or abdomen. The recommended treatment duration is limited to two years due to concerns about the potential risk of osteosarcoma, a type of bone cancer. Therefore, teriparatide is usually reserved for patients with severe osteoporosis or those who have experienced fractures despite receiving other treatments.

Teriparatide is particularly effective in increasing bone mineral density in the spine, reducing the risk of vertebral fractures. It has also been shown to reduce the risk of non-vertebral fractures, including hip fractures, in postmenopausal women with severe osteoporosis. The medication is generally well-tolerated, although some common side effects may include nausea, dizziness, headache, and leg cramps.


It is important to note that teriparatide is not suitable for everyone. It is contraindicated in individuals with a history of hypercalcemia, skeletal malignancies, or Paget’s disease of bone. It is also not recommended for use in pregnant or breastfeeding women.

As with any medication, there are potential risks and benefits associated with teriparatide. Therefore, it is essential for individuals considering this treatment to have a thorough discussion with their healthcare provider. They will evaluate the patient’s medical history, perform necessary tests, and assess the overall risk-benefit profile to determine if teriparatide is the appropriate treatment option.


In conclusion, teriparatide is a medication used in the treatment of osteoporosis. It works by stimulating bone formation and increasing bone mineral density. While it has shown efficacy in reducing the risk of fractures, its use is limited to a maximum of two years due to safety considerations. Individuals considering teriparatide should consult their healthcare provider for a comprehensive evaluation and personalized treatment plan.